|
市場調查報告書
大塚製藥:企業概要
Otsuka Pharmaceutical Co., Ltd: PharmaVitae Report
| 出版商 |
Datamonitor |
| 出版日期 |
2011年10月 |
商品編碼 |
229419 |
| 內容資訊 |
英文 Pages: 63 |
| 價格 |
|
|
大塚製藥:企業概要 是由出版商Datamonitor在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 63 價格從美金5700起跳。
本報告提供在醫藥品產業的大塚製藥，其現在·未來的業績趨勢相關分析，主要產品的開發·銷售趨勢，財務業績的實際成果值及預測值(都是6年份)，企業簡介，產業策略的資訊，為您概述為以下內容。
執行摘要
- 主要的分析結果
- 處方藥的銷售額預測
- 主要的發展
- SWOT分析
關於本報告
- PharmaVitae:企業資料資料庫
- 本報告的章節組成
- 策略性考察
- 企業概要
- 銷售額·產品分析
- 財務分析
- 產品分析
- 資料的資訊來源
策略性考察
- 主要的分析結果
- Abilify是大塚製藥的成長軌道核心
- 產品組成的多樣化與外製化策略
企業概要
- 主要的分析結果
- 背景
- 企業的發展
- 企業合併·收購(收購與合併)的歷史沿革
- Meretek Diagnostics的收購
- Interpharma Praha stock的收購
- Nutrition & Sante holding company的收購
- 取得Nanjing Techbond的過半數股票
- 目前企業結構
- 醫藥品產業部門結構
銷售額分析
- 主要的分析結果
- 處方藥的銷售額與其增加率分析(2004∼2016年)
- 產品分析
- 產品分析(2004∼2010年)
- 產品分析(2010∼2016年)
- 治療領域分析
- 地區分析
- 新銷售/主力品/專利結束分析
- 說明
- 新銷售分析(2010∼2016年)
- 主力品分析(2010∼2016年)
- 專利結束分析(2010∼2016年)
- 新銷售/主力品/專利結束的形態(2010∼2016年)
- 分子類型分析
- 外部分析
產品分析
TS-1
附錄
Description
Introduction
This analysis examines the historical and forecast performance for Otsuka in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Otsuka's strategic outlook across the next 6 years.
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
- Otsuka's performance will deteriorate through to 2016, as key growth drivers mature and decline. Notably, Otsuka's performance will be shaped by the decline in sales of its biggest drug, Abilify, due to generic erosion from 2015. With modest gains forecast for its launch pipeline, Otsuka will increasingly rely on external deals to achieve growth.
Your key questions answered
- Benchmark Otsuka's performance against key rivals in the prescription pharmaceutical sector
- Assess how successful Otsuka will be in diversifying its business focus and reducing its reliance on sales of the blockbuster Abilify.
TOC
Executive Summary
- Key findings
- Otsuka prescription pharma sales outlook
- Key developments
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
ABOUT THIS REPORT
- PharmaVitae Explorer database
- Chapter structure
- Strategic insight
- Company introduction
- Sales analysis
- Financial analysis
- Product analysis
- Data sourcing
STRATEGIC INSIGHT
- Key findings
- Abilify is central to Otsuka's growth trajectory
- Portfolio diversification and externalization strategy
COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- M&A history
- Acquisition of Meretek Diagnostics
- Acquisition of Interpharma Praha stock
- Acquisition of Nutrition & Sante holding company
- Acquisition of majority stake in Nanjing Techbond
- Current corporate structure
- Pharmaceuticals business unit structure
- Pharmaceuticals business unit structure
- Consumer health
SALES ANALYSIS
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2004-16
- Product analysis
- Product analysis, 2004-10
- Product analysis, 2010-16
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2010-16
- Core analysis, 2010-16
- Expiry analysis, 2010-16
- Launch/core/expiry configuration, 2010-16
- Molecule type analysis
- Externalization analysis
PRODUCT ANALYSIS
TS-1
APPENDIX
- References
- Exchange rates
|
